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EXPERT OPINION
Abstract: Aripiprazole has been approved by regulatory agencies for the treatment of
schizophrenia and bipolar I disorder. Although it is a dopamine partial agonist, it also has
substantial binding affinity for the serotonin 5HT2A receptor. Several double-blind randomized
clinical trials have established the efficacy and tolerability of aripiprazole within the dose
range of 10–30 mg/day for schizophrenia, and 15–30 mg/day for manic or mixed states
associated with bipolar I disorder. Relatively few comparative trials with other second-
generation antipsychotics have been published for schizophrenia, with none available for
bipolar disorder. The evidence so far suggests that in terms of efficacy for schizophrenia,
aripiprazole is superior to placebo and haloperidol (long term), similar to perphenazine and
risperidone, and inferior to olanzapine. Its tolerability profile in patients with schizophrenia
appears superior to haloperidol, perphenazine, risperidone, and olanzapine. Efficacy in treating
manic or mixed states was established in placebo-controlled trials. Among some patients
with bipolar disorder, akathisia and gastrointestinal (GI) complaints can emerge at the start of
treatment; however, the GI symptoms were time-limited in many instances. Appropriate dosing
may also be important in individualizing therapy to improve tolerability, with lower starting
doses becoming more important when adding to, or switching from, another antipsychotic.
Aripiprazole appears to have a low propensity for weight gain, a favorable metabolic profile,
and no association with hyperprolactinemia.
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Introduction
Aripiprazole was approved by the United States Food and Drug Administration in
November 2002 for the treatment of schizophrenia. Its introduction was heralded by
some as a “third-generation” antipsychotic, as it was the first dopamine partial agonist
anti-schizophrenia drug to be marketed. Since then, there has been greater appreciation
of the more complex nature of receptor binding affinities, and aripiprazole can also
be classified as a medication with significant 5HT2A-antagonism, and with still other
additional secondary binding characteristics which may be clinically important in
individual patients. Other events since the product launch of aripiprazole have been
the emergence of second-generation antipsychotics as mood stabilizers, with almost
all of them, including aripiprazole, being approved by regulatory authorities for the
indication of bipolar mania. This review will briefly examine the most current
information on mechanism of action of aripiprazole and discuss in more detail the
clinical trial evidence supporting its use in both schizophrenia and bipolar disorder.
Reviewing studies has been made somewhat easier by the recent introduction of
online clinical trial registries that provide information not always found in the
published scientific literature; however, details are not consistently available for all
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registered studies. The efficacy and safety of aripiprazole
is discussed separately for both schizophrenia and bipolar
disorder, followed by a discussion on optimal dosing and
general utility of this agent. In general, less information is
available on the use of aripiprazole for bipolar disorder than
it is for schizophrenia. Greater weight is placed on peer-
reviewed publications, together with actual data provided
from disclosures found in online registries. References to
posters and abstracts, which are typically not subject to peer
review, are made sparingly.
Mechanism of action
Aripiprazole is a quinolinone derivative with demonstrated
partial agonist activity at D2 receptors (Burris et al 2002).
This observation has led to the concept of aripiprazole being
a “dopamine receptor stabilizer”, decreasing dopamine
activity when it is abnormally high, and increasing it when
abnormally low. This has been used to explain aripiprazole’s
efficacy in reducing the symptoms of schizophrenia without
causing much in the way of extrapyramidal effects.
However, antagonist activity at serotonin 5HT2A receptors
(Shapiro et al 2003) is also important in explaining the
putative mechanism of action, and brings aripiprazole in
line with the other second-generation antipsychotics as all
being essentially serotonin-dopamine antagonists. Other
receptor-binding activities, including at 5HT1A and D3
receptors, may become important in some patients at some
doses, and reflect the complexities of attempting to predict
specific therapeutic benefits from specific binding
characteristics of antipsychotics, which may or may not be
relevant to the individual being treated (Stahl 2002;
Shayegan and Stahl 2004). Further discussion of receptor-
binding characteristics for aripiprazole, including animal
studies, as well as reviews of its chemistry and
pharmacokinetic properties, can be found elsewhere
(McGavin and Goa 2002; Harrison and Perry 2004; Bhati
2005; Fleishhacker 2005).
Partial agonism at the D2 receptor may have unintended
consequences for some patients already being treated with
another antipsychotic. DeQuardo (2004) described 2 cases
of exacerbation of paranoia and anger in patients with
schizophrenia when aripiprazole (at 15 mg/day and 10 mg/
day) was added to stable doses of haloperidol decanoate
and high doses of olanzapine (60  mg/day). The agonist
effects of aripiprazole on dopamine neurotransmission in
the limbic areas was proffered as an explanation for the
exacerbation of psychosis, and the author recommended
starting aripiprazole at lower doses (5 mg/day) when adding
it to the regimens of chronically ill, tenuously controlled
psychotic patients. A similar report was published of a patient
with schizoaffective disorder experiencing a worsening of
symptoms when aripiprazole 15 and then 30  mg/day was
added to a regimen of quetiapine 800 mg/day (Reeves and
Mack 2004). Worsening of psychosis was also reported in a
case series of 4 patients with schizophrenia or
schizoaffective disorder, where aripiprazole (15–30 mg/day)
was added to second-generation antipsychotics
(Ramaswamy et al 2004). Barnas et al (2005) report on a
patient with schizoaffective disorder who experienced
psychotic and manic symptoms, necessitating hospital
admission, when her antipsychotic was switched from
perphenazine to aripiprazole. Worsening psychotic
symptoms with aripiprazole in two patients with chronic
schizophrenia was also reported by Glick et al (2006). One
of the patients described in that report initially did well with
aripiprazole but then had an exacerbation requiring a change
to another antipsychotic. The second patient experienced a
worsening of psychotic symptoms upon the initiation of
aripiprazole. A number of possible explanations were
provided, including that this could be ascribed to the natural
course of the disease. Other explanations included an
increased dopamine effect owing to the addition of
aripiprazole in patients who have been subject to chronic
dopamine blockade, as well as the displacement of lower
binding affinity antipsychotics by aripiprazole at the
dopamine receptor, and pharmacokinetic interaction among
multiple medications.
Efficacy
Schizophrenia (Table 1)
Almost all of the controlled clinical trials of aripiprazole
have been conducted by its manufacturer. Some are
published as peer-reviewed journal articles, some as articles
in supplements to journals, and yet others as poster
presentations at scientific meetings. Recently, additional
information has become available on the world wide web
in the form of clinical trial registries. Although the latter
are not peer reviewed, they do contain substantially more
information than the abstracts encountered at scientific
meetings. Below are descriptions of the studies done that
illuminate the efficacy of aripiprazole in the treatment of
schizophrenia.
The first published report of a randomized clinical trial
examining aripiprazole’s efficacy in treating schizophreniaNeuropsychiatric Disease and Treatment 2006:2(4) 429
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was a double-blind 4-week study conducted in the USA
comparing two doses of aripiprazole (15 mg/day and 30 mg/
day) vs placebo, with haloperidol 10 mg/day acting as an
active control (Kane et al 2002). A total of 414 patients with
acute schizophrenia were randomized to each of the four
groups, and 60% completed the entire 4 weeks (55% for
placebo, 67% for aripiprazole 15 mg/day, 59% for
aripiprazole 30 mg/day, and 60% for haloperidol). Patients
Table 1 Aripiprazole for the treatment of schizophrenia, randomized clinical trials
Reference Duration N Aripiprazole, dose, N Comparators, dose, N Comments
(weeks)
Marder et al 2003 4 103 5–30 mg (N=34) Placebo (N=35), haloperidol Phase II study reported in a
5–20 mg (N=34) pooled safety analysis
Marder et al 2003 4 307 2 mg (n=59), 10 mg Placebo (N=64), haloperidol Phase II study reported in a
(N=60), 30 mg (N=61) 10  mg (N=63) pooled safety analysis
Marder et al 2003 4 305 20 mg (N=101), Placebo (N=103) Phase III study reported in a
30 mg (N=101) pooled safety analysis
Kane et al 2002 4 414 15 mg (N=102), Placebo (N=106), Haloperidol did not separate
30 mg (N=102) haloperidol 10 mg (N=104) from placebo on the
responder analysis; included in
a pooled safety analysis
(Marder et al 2003)
Potkin et al 2003 4 404 20 mg (N=101), Placebo (N=103),
30 mg (N=101) risperidone 6mg (N=99)
Bristol-Myers Squibb 6 420 10 mg (N=103), Placebo (N=107) Conversion to open-label
2001 (CN138-001)  15 mg (N=103),  aripiprazole treatment at
20 mg (N=97) the end of week 3 for
non-responders; included in a
pooled safety analysis
(Marder et al 2003)
Bristol-Myers Squibb 6 (and 140) 703 15–30 mg (N=355) Olanzapine 10–20 mg (N=348) Not yet published
 2005 (CN138-003) 
Saha et al 2002 15 days 40 30 mg (N=12), None Safety and tolerability study;
45 mg (N=7), 60 mg (N=7), available as a poster only
75 mg (N=7), 90 mg (N=7)
Bristol-Myers Squibb 28–52 317 15 –30 mg (N=156) Olanzapine 10–20 mg (N=161) Safety and tolerability study;
2004a (CN138-002) originally designed with a
and McQuade 12-week acute phase followed
et al 2004 by a long-term extension
phase, protocol amendment
revised the endpoints to Week
 26 (and 52) instead of
Week 12
Bristol-Myers Squibb 6 300 15–30 mg (N=154) Perphenazine 8–64 mg (N=146) Not yet published; treatment
2004b (CN138-032) failure to olanzapine or
and Kane et al 2003 risperidone prospectively
determined
Pigott et al 2003 26 310 15 mg (N=155) Placebo (N=155)
Kasper et al 2003 52 1294 30 mg (N=861) Haloperidol 10 mg (N=433)
Bristol-Myers Squibb 52 (extension)214 15–30  mg (N=104) Olanzapine 10–20 mg (N=110) Open-label extension to Pigott
2004c (CN138-047) et al (2003)
Bristol-Myers Squibb
2004d (CN138-087) 8-24 1599 10–30  mg (N=1295) Other antipsychotic (N=304) Open-label “Broad
and Tandon et al 2006 Effectiveness Trial with
Aripiprazole”Neuropsychiatric Disease and Treatment 2006:2(4) 430
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randomized to aripiprazole or haloperidol experienced
reductions in their total Positive and Negative Syndrome
Scale scores (PANSS) superior to that seen for placebo, but
a responder analysis demonstrated no difference between
haloperidol and placebo in terms of a 30% reduction in total
PANSS from baseline. In terms of PANSS subscales,
aripiprazole 15  mg/day and haloperidol, but not aripiprazole
30 mg/day, significantly improved the PANSS negative score
compared with placebo. All three active treatment groups
demonstrated superiority over placebo on the PANSS
positive score.
The second key registration study was again 4 weeks in
duration, but this time the active comparator was risperidone
6mg/day (Potkin et al 2003). A total of 404 patients with
acute schizophrenia in the USA were randomized to one of
two doses of aripiprazole (20 mg/day or 30 mg/day), placebo,
or risperidone. As with the Kane et al study (2002), 60%
completed the entire 4 weeks (50% for placebo, 60% for
aripiprazole 20 mg/day, 66% for aripiprazole 30 mg/day, and
63% for risperidone). Patients randomized to aripiprazole
or risperidone experienced reductions on the primary
efficacy measures (PANSS total, PANSS positive, and
Clinical Global Impressions-Severity [CGI-S]) superior to
that seen for placebo. All three active treatment groups
demonstrated superiority over placebo in the responder
analysis (as defined by a 30% or more decrease from the
baseline PANSS total score or a score of very much
improved or much improved on the CGI-Improvement
(CGI-I) scale).
Available on the Bristol-Myers Squibb Clinical Trials
Disclosure Database (URL: http://ctr.bms.com/ctd/), are the
results of study CN138-001, a Phase III multicenter
randomized, double-blind, placebo-controlled study of 3
fixed doses of aripiprazole conducted in the USA and
Canada with patients with acutely relapsed schizophrenia
(Bristol-Myers Squibb 2001). A total of 420 patients were
randomized to receive 1 of 3 doses of aripiprazole (10 mg/
day, 15  mg/day, and 20  mg/day) or placebo for 6 weeks.
Patients not responding by the end of Week 3, 4, or 5 were
discontinued from blinded treatment and were offered open-
label treatment with aripiprazole 20 mg/day for the
remaining weeks. All participants were offered participation
in a double-blind extension phase for an additional 46–134
weeks (where they were randomized to receive either 10–
15 mg/day or 20–30 mg/day of aripiprazole). There was a
large attrition rate, and only 34% of the randomized patients
completed 6 weeks of double-blind treatment. All three
active treatment groups showed statistically significantly
greater improvement than placebo for the PANSS total,
PANSS positive and negative, CGI-S, and CGI-I scores,
and all active treatment groups were statistically
significantly superior to placebo in the PANSS responder
analysis (30% reduction).
These three short-term studies of aripiprazole (Kane et
al 2002; Potkin et al 2003; Bristol-Myers Squibb 2001)
established the acute efficacy of aripiprazole with
demonstrated superiority over placebo. However, in the two
studies that employed active controls, the protocols were
not designed to directly compare aripiprazole with
haloperidol (Kane et al 2002) or risperidone (Potkin et al
2003) per se. Thus additional double-blind studies are
needed, particularly directly comparing aripiprazole with
other second-generation antipsychotics. A multi-center,
international, double-blind, randomized, comparative study
of aripiprazole and olanzapine among patients with acute
schizophrenia has recently been reported in the Bristol-
Myers-Squibb Clinical Trials Disclosure Database as study
CN138-003 (Bristol-Myers Squibb 2005). A total of 703
patients who were having an acute relapse were randomized
to receive either olanzapine 10–20 mg/day or aripiprazole
10–20 mg/day for 6 weeks. At the conclusion of the 6 weeks,
patients who demonstrated improvement were continued
into an extended double-blind treatment period lasting up
to 140 weeks. In all, 71% of the randomized patients in the
aripiprazole group and 78% of the randomized patients in
the olanzapine group completed the entire 6 weeks. Of the
randomized subjects, 65% of the aripiprazole patients and
74% of the olanzapine patients entered the extension phase.
At Week 6, patients in both treatment groups improved on
their mean change from baseline PANSS total score, but
the improvement was greater for olanzapine (–27.36) than
aripiprazole (–22.15) (a minimum PANSS of 60 was
required for randomization but the report does not provide
the mean baseline PANSS scores for the participants). A
prespecified criterion was set for noninferiority of
aripiprazole, which was not met. At Week 6 statistically
significant differences in favor of the olanzapine group were
also observed in the mean change from baseline in the CGI-
S, PANSS positive, PANSS negative, and Montgomery
Asberg Depression Rating Scale (MADRS) scores. In
addition, statistically significant differences in favor of the
olanzapine group were demonstrated in the mean CGI-I and
the percentage of responders at Week 6. When examining
observed cases only, rather than last observation carried
forward, statistically significant differences in favor of the
olanzapine group were demonstrated in the mean changeNeuropsychiatric Disease and Treatment 2006:2(4) 431
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from baseline on only the PANSS total, CGI-S, and
MADRS. The mean change from baseline to Week 6 in the
PANSS positive, PANSS negative, and the Week 6 mean
CGI-I and the percentage of responders were not statistically
significant among the observed cases.
The above trials represent evidence for acute treatment.
However, patients with schizophrenia typically require
treatment with antipsychotics indefinitely. Moreover, long-
term treatment is expected to result in further amelioration
of not only positive symptoms, but also negative symptoms
and cognitive symptoms (DeQuardo and Tandon 1998).
Long-term treatment of schizophrenia with aripiprazole was
established in 2 pivotal reports (Kasper et al 2003; Pigott et
al 2003). In the first, a 26-week randomized, double-blind,
multicenter study conducted internationally, 310 patients
with stable schizophrenia were randomized to aripiprazole
15 mg/day or placebo (Pigott et al 2003). Stability was
defined as no significant improvement or worsening of
symptoms within the past 3 months, but patients enrolled in
the study were still experiencing significant symptomatology
as evidenced by a mean baseline PANSS of 82 (a score of
at least 60 was needed for study entry). Patients also had to
score no more than 4 (moderately ill) on the CGI-S and not
be hostile or uncooperative based on the pertinent PANSS
items being less than or equal to 4 (moderately ill). Overall,
37% completed the entire 26-week study (46% for
aripiprazole and 29% for placebo). The time to relapse
following randomization was significantly longer for
aripiprazole than placebo. Aripiprazole was significantly
superior to placebo from baseline to endpoint in PANSS
total, PANSS positive, and CGI-S scores. A 52-week open-
label extension was offered to patients (study CN138-047)
(Bristol-Myers Squibb 2004c) where a total of 214 patients
were randomized to either aripiprazole 15–30 mg/day or
olanzapine 10–20 mg/day. A total of 69% completed the
open-label extension (63% for aripiprazole and 74% for
olanzapine). There were no statistically significant
differences on the efficacy measures between the two
treatment arms.
The second report of a double-blind long-term clinical
trial of aripiprazole in patients with schizophrenia was a
pooled analysis of two similar protocols (Kasper et al 2003).
A total of 1294 patients in acute relapse who had previously
responded to antipsychotic medications were randomized
to receive either aripiprazole 30 mg/day or haloperidol
10 mg/day for 52 weeks. Overall, 38% of patients completed
the entire 52-week study (43% for aripiprazole and 30%
for haloperidol). Aripiprazole demonstrated significantly
greater improvements for PANSS negative and MADRS
scores than haloperidol. The time to discontinuation for any
reason was significantly greater with aripiprazole than with
haloperidol.
Thus, two published double-blind studies have
demonstrated the long-term efficacy of aripiprazole, one
(Pigott et al 2003) showing superiority to placebo, the other
(Kasper et al 2003) showing superiority to haloperidol.
Long-term, double-blind studies comparing aripiprazole
with other second-generation antipsychotics are needed. The
multi-center, international, double-blind, randomized,
comparative study of aripiprazole and olanzapine (Bristol-
Myers Squibb 2005) allowed for an extended double-blind
treatment period lasting up to 140 weeks for patients who
had a response in the first 6 weeks, as defined by a CGI-I of
3 or less, or a PANSS total improvement of 20% or greater
from baseline. Data for up to Week 52 are available. Attrition
was high, with 61% of the randomized patients in the
aripiprazole group and 53% of the randomized patients in
the olanzapine group discontinuing the study before Week
52. The discontinuation rate over time was statistically
significantly higher in the aripiprazole group than in the
olanzapine group for the period up to Week 52. For the
PANSS total, statistical differences favoring olanzapine
were seen in the last observation carried forward dataset,
while no significant differences were observed in the
observed cases analyses. The efficacy scores for patients
who were not eligible to continue in the extension phase
because of only partial response at Week 6 were also
carried forward to Week 52, and contributed to the
differences in efficacy observed between the two
treatment groups after Week 6 on the last observation
carried forward analysis.
Additional information on the comparative efficacy of
aripiprazole and olanzapine is available from a safety and
tolerability study, part of which has been published in a
journal supplement (McQuade et al 2004), and part can be
found in the Bristol-Myers Squibb Clinical Trials Disclosure
Database as study CN138-002 (Bristol-Myers Squibb
2004a). In this international study, 317 patients with
schizophrenia in acute relapse and who required
hospitalization were randomized to receive either
aripiprazole (15–30 mg/day) or olanzapine (10–20 mg/day)
for 52 weeks. Patients were required to have at least a score
of 60 on the PANSS total. Patients remained hospitalized
until at least the Day 4 visit. Patients with a CGI-I of 1–3
could be discharged, based on clinical judgment. Patients
with a CGI-I score of at least 4 (no improvement orNeuropsychiatric Disease and Treatment 2006:2(4) 432
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worsening) at Week 6 were discontinued from the study.
Patients unable to tolerate the lowest dose of study
medication and patients who required rehospitalization for
worsening schizophrenia were also discontinued from the
study. At the end of 12 weeks of study therapy, patients
with a CGI-I of 1–3 or a at least  20% decrease from baseline
in PANSS total were given the option to continue in the
study on blinded treatment for 40 additional weeks. A
protocol amendment changed the primary and secondary
endpoints from Week 12 to Week 26; the reason provided
was that long-term weight gain data could be captured.
Attrition rates were high. Only 28% of the 317 randomized
patients completed 26 weeks of the protocol, with 16%
completing 52 weeks (87% of the aripiprazole patients and
81% of the olanzapine patients discontinued on or before
Week 52). The responder analysis showed that aripiprazole
and olanzapine had similar improvement at Week 52 using
the observed cases data set, 20/21 (95%) of aripiprazole
patients meeting the definition of response vs 29/30 (97%)
of olanzapine patients. Aripiprazole and olanzapine had
similar improvement on the PANSS total, PANSS positive,
PANSS negative, CGI-S, and CGI-I scores. The treatment
groups also had similar results on the MADRS. The major
shortcoming of this trial in terms of assessing efficacy is
that no information was provided on comparative efficacy
at Week 12, before enrollment into the extension phase for
responders. In addition, comparison of the completers
focuses on patients who have done relatively well and
differences between treatment arms would have been
difficult to detect, particularly with the small numbers of
patients for which data were available.
Patients with treatment-refractory schizophrenia form a
subgroup that is usually excluded from registration studies.
Few controlled studies are available (Citrome et al 2002),
and meta-analyses have generally supported clozapine as
the gold standard for these difficult-to-treat patients
(Wahlbeck et al 1999; Chakos et al 2001). Available on the
Bristol-Myers Squibb Clinical Trials Disclosure Database
as study CN138-032 (Bristol-Myers Squibb 2004b) and
presented as a poster (Kane et al 2003), is a Phase III
randomized double-blind clinical trial conducted in the US
and Canada that tested the hypothesis that aripiprazole is
superior to perphenazine in treatment-resistant
schizophrenia. Patients were considered treatment resistant
if they had not experienced satisfactory symptom relief
despite at least 2 periods of treatment during the past 2 years,
each lasting at least 6 weeks, with adequate doses of
antipsychotic medication agents (of which at least 1 was a
first-generation antipsychotic). Patients were required to
have a PANSS total of at least 75 and a score of at least 4
(moderately ill) on at least 2 of the following PANSS items:
conceptual disorganization, suspiciousness, hallucinatory
behavior, or delusions; and a score of at least 4 (moderately
ill) on the CGI-S. Eligible patients underwent a 4- to 6-
week, prospective, open-label treatment trial with either
olanzapine (10–20 mg/day) or risperidone (2–8 mg/day),
depending on their previous treatment history, to confirm
treatment-resistance. Patients were required to receive at
least 15 mg olanzapine or 6 mg risperidone per day for a
minimum of 3 weeks during this phase in order to be
considered for continuation in the study. Patients with
improvement as defined by a reduction in the PANSS total
score of at least 20% and a CGI-S of 1–3 (normal to mildly
ill) at any time during this phase were discontinued from
the study. Patients who failed to show this improvement
were randomized to receive flexible doses of either
perphenazine (8–64 mg/day) or aripiprazole (15–30 mg/day)
for 6 weeks. At the completion of the double-blind phase,
patients were provided the option to receive open-label
aripiprazole for an additional 98–109 weeks. A total of 416
patients were enrolled into the phase confirming treatment
resistance to olanzapine or risperidone, and a total of 300
patients categorized as treatment resistant were subsequently
randomized to aripiprazole or perphenazine. Overall, 75%
of patients completed the double-blind phase (71% for
aripiprazole and 79% for perphenazine). Overall, 27% and
25% of patients responded to aripiprazole and perphenazine,
respectively, based on a CGI-I of 1–2, or at least a 30%
decrease in PANSS total. There was no significant difference
between the perphenazine and aripiprazole groups in the
primary efficacy measure, mean change from baseline to
Week 6 in the PANSS total (improvements of 9.8 for
aripiprazole and 10.5 for perphenazine). Neither were there
any statistically significant differences on the secondary
efficacy measures, PANSS positive and negative scores,
CGI-S, CGI-I, percentage of categorical responders, and
the rate of discontinuation owing to lack of efficacy.
Thus efficacy of aripiprazole for the treatment of acute
schizophrenia was demonstrated in short-term clinical
trials comparing it with placebo. Superiority to
haloperidol was demonstrated in a longer-term trial, but
the efficacy of aripiprazole appears inferior to that of
olanzapine in short- and long-term trials. Among
treatment-resistant patients, aripiprazole demonstrated
similar improvement to that seen with perphenazine.
Tolerability will be discussed later.Neuropsychiatric Disease and Treatment 2006:2(4) 433
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Bipolar disorder (Table 2)
The first published pivotal trial of aripiprazole for the
treatment of bipolar disorder was a multi-center study
conducted in the US and reported by Keck et al (2003). A
total of 262 patients with bipolar I disorder, manic or mixed
episode, who were experiencing an acute relapse that
required hospitalization, were randomized to either
aripiprazole 30 mg/day or placebo for 3 weeks. Subjects
were required to have a minimum Young Mania Rating Scale
(YMRS) score of at least 20. Patients not responding at the
end of Week 2 were discontinued from double-blind
treatment and offered open-label treatment with aripiprazole.
Overall, 31% of the patients completed the study (42% for
aripiprazole and 21% for placebo). Although the starting
dose of aripiprazole was 30 mg/day, the dose could be
reduced to 15 mg/day for tolerability if required. The
majority of patients (86%) randomized to aripiprazole
remained on the 30 mg/day dose for the entire study. The
mean dose of aripiprazole at endpoint was 27.9 mg/day.
Patients receiving aripiprazole demonstrated significant
improvement on the YMRS compared with placebo.
Response, defined as a 50% reduction in the YMRS, was
greater for aripiprazole than placebo at all time points, with
endpoint response rates of 40% and 19% respectively. Other
measures corroborated the advantage of aripiprazole vs
placebo, including measures of severity of illness.
A second positive controlled 3-week trial of aripiprazole
compared with placebo for acute manic or mixed episodes
in patients with bipolar I disorder was recently reported by
Sachs et al (2006). The design was similar to the study
reported by Keck et al (2003), and was also conducted in
the US. A total of 272 hospitalized patients were
randomized to receive either aripiprazole 30 mg/day or
placebo. Overall, 53% of the patients completed the study
(55% for aripiprazole and 52% for placebo), thus the
attrition rate was substantially lower than in the Keck et
al (2003) study. The majority of patients (85%)
randomized to aripiprazole remained on the 30 mg/day
dose for the entire study. The mean dose of aripiprazole
at endpoint was 27.7 mg/day. Patients receiving
aripiprazole demonstrated significant improvement on the
YMRS compared with placebo. Response, defined as a
50% reduction in the YMRS, was greater for aripiprazole
than placebo at all time points, with endpoint response
rates of 53% and 32% respectively. Other measures
supported the advantage of aripiprazole vs placebo,
including measures of severity of illness.
Not published and never publicly presented, was a third
double-blind, randomized clinical trial of aripiprazole in
patients with bipolar I mania. Some information on this trial
was included in a press release from the manufacturer
(Bristol-Myers Squibb 2003b). In this study, aripiprazole
did not show a statistically significant separation from
placebo. The press release noted that aripiprazole
demonstrated symptom improvement comparable with that
of the other studies, but that there was a high placebo
response rate (approximately 40%). Further details are not
available, other than patients in the study were randomized
to receive aripiprazole 15 or 30 mg/day or placebo (Lyseng-
Williamson and Perry 2004).
Table 2 Aripiprazole for the treatment of bipolar mania, randomized double-blind clinical trials
Reference Duration N Aripiprazole, dose, N  Comparators, dose, N Comments
(weeks)
Keck et al 2003 3 262 30 mg (N=130) Placebo (N=132)
Vieta et al 2005 12 347 15–30 mg (N=175) Haloperidol 10–15mg Benztropine or other
(N=172) anticholinergics were not
permitted
Bristol-Myers Squibb ? ? 15 mg (N=?), Placebo (N=?) Response to aripiprazole did not
 2003b 30 mg (N=?) separate from placebo; data not
published, nor posted in the
Bristol-Myers Squibb Clinical Trials
Disclosure Database
Sachs et al 2006 3 272 30 mg (N=137) Placebo (N=135)
Bristol-Myers Squibb 26 161 15–30 mg (N=77) Placebo (N=83)
2003a (CN138-010),
and Keck et al
2006Neuropsychiatric Disease and Treatment 2006:2(4) 434
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Thus, data from 2 out of 3 short-term double-blind trials
support the use of aripiprazole for the treatment of acute
manic or mixed episodes. These trials did not address what
the utility of aripiprazole was after the first 3 weeks of
treatment. Moreover, no active comparator (or active
control) was employed. Additional information comes from
an international, 12-week, double-blind, randomized clinical
trial comparing aripiprazole with haloperidol (Vieta et al
2005). In contrast to the 3-week studies involving placebo,
patients in this trial could participate regardless of whether
they were inpatients or outpatients, as long as they were
experiencing an acute manic or mixed episode and had a
YMRS score of at least 20. Patients were randomized to
receive aripiprazole
 15 mg/day or haloperidol 10 mg/day.
There were 2 phases to the trial: phase 1 included the first 3
weeks and represented an acute phase of treatment, and
phase 2 which consisted of Weeks 4–12. At the end of Week
1 or 2, patients showing a poor response to therapy had the
option to have their dose of aripiprazole increased to 30 mg/
day or
 haloperidol to 15 mg/day. Patients intolerant of the
higher dose
 could return to their initial lower dose.
Anticholinergic medications were not permitted at any time
during the trial. Patients unable to
 tolerate 15 mg/day of
aripiprazole or 10 mg/day of haloperidol at any time, and
patients who remained significantly symptomatic at the end
of Week 3 were discontinued from the trial.
 Thus, Weeks
4–12 could be viewed as an evaluation of maintenance of
response. A total of 347 patients were randomized to
aripiprazole or haloperidol. At Week 3, the average daily
dose of aripiprazole
 was 22.6 mg/day and haloperidol
11.6 mg/day. At Week 12, average daily doses were 21.6 mg
and 11.1 mg respectively. Overall, 66% of the patients
completed the first 3 weeks of treatment (77% for
aripiprazole and 55% for haloperidol). Overall, 40% of the
patients completed the entire 12 weeks of the study (51%
for aripiprazole and 29% for haloperidol). Response rate to
treatment showed no statistically significant differences
between aripiprazole and haloperidol at 3 weeks, but a
difference emerged at 12 weeks (response rate was 50% for
aripiprazole and 28% for haloperidol). Both aripiprazole
and haloperidol treatment resulted in marked improvement
in the YMRS from baseline to Week 12 (mean reductions
of 19.9 for aripiprazole and 18.2 for haloperidol, from mean
baselines of 31.1 and 31.5, respectively). Among completers
the reductions in YMRS were larger, 29.0 for aripiprazole
and 27.4 for haloperidol. Among completers, more patients
on aripiprazole were in remission (defined as YMRS less
than 12) at Week 12 than patients receiving haloperidol,
with remission rates of 50% and 27% respectively. Both
treatments demonstrated similar reductions on measures of
disease severity. Of additional interest were measures of
depression. Reductions
 in depressive symptoms observed
with aripiprazole were larger than with haloperidol and this
was statistically significant at Week 3, but not at Week 12.
Significantly more patients on aripiprazole than with
haloperidol demonstrated a 50% or greater decrease on the
MADRS
 at Weeks 3 and 12.
Recently published (Keck et al 2006), and available in
the Bristol-Myers Squibb Clinical Trials Disclosure
Database as study CN138-010 (Bristol-Myers Squibb
2003a), is a 26-week, double-blind, placebo-controlled,
international study comparing aripiprazole with placebo for
maintaining the stability of patients with bipolar I disorder.
The primary outcome measure was time to relapse (time to
discontinuation owing to lack of efficacy). Patients were
considered as relapsing if they were hospitalized for manic
or depressive symptoms, or required changes in their
medications. Patients who had recently completed a 3-week
acute mania study of aripiprazole were eligible to enter, but
patients who had recently received inpatient treatment for a
manic or mixed episode and had not participated in a 3-
week aripiprazole study were also eligible. Patients entered
the study as inpatients or as outpatients. The study had 3
phases: a stabilization phase lasting 6–18 weeks, a
maintenance phase lasting 26 weeks (the main phase of the
study), and an optional extension phase lasting up to 74
additional weeks. During the stabilization phase, patients
received open-label treatment with aripiprazole at a starting
dose of 30 mg/day, with a possible dose reduction to 15 mg/
day in case tolerability issues emerged. The mean dose of
aripiprazole during the stabilization phase was 25.3 mg/day.
Patients would continue in this phase until their bipolar
symptoms were considered stable, defined by a YMRS of
less than or equal to 10, and a MADRS of less than or equal
to 13 for 4 consecutive visits over a minimum of 6 weeks.
The mean duration of the stabilization phase was 89 days
(median 85 days). Once stable, patients were randomized
to receive either aripiprazole or placebo. The dose of
aripiprazole remained at the same amount as they had been
receiving during open-label treatment, either 15 mg/day or
30 mg/day, and could be changed at any time during the
study, as necessary, based on efficacy and tolerability. The
mean dose of aripiprazole in the double-blind (maintenance)
phase was 24.3 mg/day. Patients who completed 26 weeks
of the maintenance phase without a relapse were initially
invited to continue on their current double-blind study drugNeuropsychiatric Disease and Treatment 2006:2(4) 435
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treatment in an extension phase for up to an additional 74
weeks. However, enrollment in the study was stopped after
45 patients had relapsed, and patients were allowed to
continue in the study only until the last randomized patient
had completed the maintenance phase, at which time the
study was terminated. A total of 567 patients entered the
stabilization phase (59% from a previous aripiprazole acute
mania trial). Overall, 37% of patients completed the
stabilization phase. A total of 196 patients were randomized
to either aripiprazole or placebo, but because of operational
problems, only 161 patients could be included in the analysis
of the primary outcome measure. Attrition was high. Overall,
42% completed the study (50% for aripiprazole and 34%
for placebo). The time to relapse of symptoms was
significantly longer with aripiprazole treatment than with
placebo. In addition, significantly fewer aripiprazole-treated
patients experienced relapse (manic, mixed, or depressive
symptoms) than those receiving placebo (25% for
aripiprazole and 43% for placebo). Aripiprazole was found
to be superior to placebo in delaying the time to a manic
relapse but no difference between the treatment groups was
observed in time to a depressive relapse. This was consistent
with the finding of lower YMRS scores and lack of
differences in the MADRS when comparing aripiprazole
with placebo.
Thus, efficacy in the short-term management of acute
manic or mixed episodes was established in comparison with
placebo, and a 12-week controlled trial revealed comparable
efficacy of aripiprazole with haloperidol after 3 weeks of
acute treatment, but superiority after 12 weeks. A 26-week
relapse prevention study demonstrated that aripiprazole was
superior to placebo in preventing relapse into mania, but
not depression.
Safety and tolerability
Schizophrenia
Marder et al (2003) reviewed safety and tolerability in a
pooled analysis of 5 of the short-term (4- to 6-week),
placebo-controlled trials of aripiprazole. Of the 1509
randomized patients, 932 received aripiprazole (dose range
2–30 mg/day), 416 placebo, and 201 haloperidol. Two of
the studies were Phase II, 3 were Phase III. The
discontinuation rate owing to adverse events with
aripiprazole treatment was similar to that for haloperidol
and placebo (7%, 8%, and 10% respectively). The most
frequent adverse events leading to discontinuation from
placebo, aripiprazole, or haloperidol included: psychosis
(6.1%, 3.6%, and 1.5% respectively), agitation (1.9%, 0.6%,
and 0% respectively), anxiety (0.2%, 0.5%, and 0%
respectively), and akathisia (0%, 0.6%, and 1.5%
respectively). A dose–response relationship with
aripiprazole for treatment-emergent adverse events was not
found, with the exception of somnolence, but the overall
incidence of somnolence was comparable with placebo
(11.0% vs 8.0%). In addition, the somnolence with
aripiprazole decreased over time: 7.7% during Days 1–7 vs
2.2% from Day 29 onwards. This was similar with placebo
(Days 1–7, 4.8% vs Day 29 onwards, 1.6%). Overall, the
adverse event rates with aripiprazole were comparable with
placebo, and lower than haloperidol for akathisia,
extrapyramidal syndrome, and somnolence. There were no
significant differences between aripiprazole and placebo on
Simpson–Angus Scale scores, no dose-dependent effects
on Barnes Akathisia scores, and significant reductions in
Abnormal Involuntary Movement Scale scores from
baseline vs placebo. Mean weight change with aripiprazole
(+0.71 kg) and haloperidol (+0.56 kg) were similar. QTc
prolongation was not observed. Serum prolactin increased
with haloperidol, but not aripiprazole. The low propensity
of aripiprazole to be associated with extrapyramidal effects
was also demonstrated over a longer period of time. In the
52-week study by Kasper et al (2003) aripiprazole had
significantly lower scores on all extrapyramidal symptoms
assessments than haloperidol. When comparing safety and
tolerability of aripiprazole with another first-generation
antipsychotic, perphenazine, among patients with treatment-
resistant schizophrenia (Bristol-Myers Squibb 2004b), the
incidence of elevated prolactin was substantially higher in
the perphenazine group compared with the aripiprazole
group. In addition, aripiprazole was less likely than
perphenazine to be associated with extrapyramidal side-
effects.
In the 26-week study by Pigott et al (2003) comparing
aripiprazole with placebo, aripiprazole was well tolerated,
with no evidence of marked sedation, hyperprolactinemia,
or prolonged QTc. Extrapyramidal symptoms were
comparable in the aripiprazole and placebo groups. Modest
mean weight loss at endpoint was evident in both groups.
In the 52-week, open-label, randomized extension (Bristol-
Myers Squibb 2004c), more patients receiving olanzapine
than patients receiving aripiprazole experienced significant
weight gain (at least 7% increase in weight) at all measured
time points, as well as greater mean change and mean
percentage change from baseline in weight. Although there
were no statistically significant differences between the twoNeuropsychiatric Disease and Treatment 2006:2(4) 436
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treatment groups for changes in extrapyramidal rating scales,
patients in the olanzapine group had a higher incidence of
extrapyramidal-related adverse events compared with
aripiprazole (18% vs 10%). Prolactin elevation was more
frequently encountered for patients receiving olanzapine
than aripiprazole. Potentially clinically significant levels of
prolactin (above the upper limit of normal) were recorded
more frequently for patients in the olanzapine group than
for the aripiprazole group. Although there were no
statistically significant differences between the two groups
in terms of fasting glucose, patients receiving olanzapine
were more likely to have elevations in cholesterol and
triglycerides. In another comparison of olanzapine and
aripiprazole, this time double-blind and specifically
designed to compare safety and tolerability (Bristol-Myers
Squibb 2004a; McQuade et al 2004), by Week 26, 37% of
olanzapine-treated patients had experienced significant
weight gain compared with 14% of aripiprazole-treated
patients. Statistically significant differences in mean weight
change were observed between treatments beginning at
Week 1 and sustained throughout the study. Changes in
fasting plasma levels of total cholesterol, high-density
lipoprotein cholesterol, and triglycerides were significantly
different in the two treatment groups, with worsening of
the lipid profile among patients treated with olanzapine. In
the observed cases data set analysis, 6/21 (29%) patients in
the aripiprazole group and 17/31 (55%) patients in the
olanzapine group had a significant weight gain at Week 52.
Patients treated with aripiprazole had a mean weight change
of –1.43 kg and a mean percent change of –0.1% at Week
52. Patients treated with olanzapine had a mean weight
increase of +5.55 kg and a mean percent increase of 6.9%
at Week 52.
Long-term safety data are also available from a large,
randomized, efficacy study of aripiprazole and olanzapine
(Bristol-Myers Squibb 2005). More patients in the
aripiprazole group (19.2%) than in the olanzapine group
(14.9%) discontinued before Week 52 for reasons of adverse
event. The adverse events with rates of at least 10% in at
least 1 treatment group were weight gain (21% for
olanzapine and 6% for aripiprazole), insomnia (21% for
olanzapine and 27% for aripiprazole), headache (8% for
olanzapine and 15% for aripiprazole), anxiety (13% for
olanzapine and 16% for aripiprazole), and somnolence (11%
for olanzapine and 4% for aripiprazole). The major
differences between olanzapine and aripiprazole in terms
of tolerability were related to weight gain and metabolic
effects. At Week 26, a significantly higher proportion of
patients in the olanzapine group experienced clinically
significant (at least 7%) weight gain than in the aripiprazole
group (31.5% and 12.5% in the olanzapine and aripiprazole
groups, respectively). This difference in weight gain was
also observed in all cohorts stratified by patients’ baseline
body mass index (BMI). Patients receiving olanzapine had
increases in mean total cholesterol, LDL-cholesterol, and
triglycerides levels, whereas they decreased in patients
randomized to aripiprazole at all time points to Week 52.
The differences in mean change from baseline to Week 52
in these levels for patients treated with olanzapine and
aripiprazole were statistically significant in favor of
aripiprazole. Serum glucose levels and glycosylated
hemoglobin levels decreased in both treatment groups.
Patients randomized to aripiprazole experienced mean
reductions from baseline in serum prolactin that were
significantly greater than patients in the olanzapine treatment
group. There was no significant difference between
treatment groups for tardive dyskinesia at Week 52.
Although the differences were small, statistically significant
treatment differences were seen in favor of olanzapine on
extrapyramidal rating scales, including the Barnes Akathisia
Global Clinical Assessment at Week 52. In contrast to the
open-label randomized extension study reported earlier
(Bristol-Myers Squibb 2004c), in this trial, more
extrapyramidal-related adverse events occurred in the
aripiprazole group than in the olanzapine group. These
extrapyramidal adverse events rarely led to discontinuation
from the 52-week study (1% of olanzapine-treated patients
and 2% of aripiprazole-treated patients). Nevertheless, more
aripiprazole patients received concomitant anticholinergic
medications (16%) than olanzapine patients (9%).
Information on the comparative safety of aripiprazole
and risperidone is limited to the single short-term study by
Potkin et al (2003). Overall, both 20 mg/day and 30 mg/day
of aripiprazole were well tolerated. A total of 44 (11%) of
403 patients in the safety sample were discontinued from
the study owing to adverse events (17% for placebo, 8%
for risperidone, 11% for aripiprazole 20 mg/day, and 8%
for aripiprazole 30 mg/day). The number of patients with
treatment-related adverse events was similar as well. The
most common adverse events were headache (27%, 31%,
28%, and 35% respectively), agitation (23%, 22%, 27%,
and 29% respectively), insomnia (22%, 20%, 31%, and 22%
respectively), anxiety (18%, 18%, 21%, and 20%
respectively), akathisia (9%, 14%, 20%, and 20%
respectively), somnolence (11%, 14%, 4%, and 19%
respectively), and dyspepsia (21%, 12%, 16%, and 16%Neuropsychiatric Disease and Treatment 2006:2(4) 437
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respectively). Measures of extrapyramidal symptoms,
including akathisia, revealed no statistically significant
differences between active treatments and placebo, and the
use of benztropine was comparable across the three active
treatment groups. Clinically significant weight gain (at least
7%) was observed in 2% of patients given placebo, 11%
for risperidone, 13% for aripiprazole 15mg/day, and 9% for
aripiprazole 30 mg/day, and statistical significance compared
with placebo on this measure was observed for all three
active arms. Serum prolactin levels decreased in patients
assigned to aripiprazole (both groups), increased minimally
in the placebo group (0.1  ng/mL), and increased by a mean
of 47.9  ng/mL in the risperidone group (the latter statistically
significantly greater than the change observed with placebo).
Categorical change in prolactin levels, defined as the
percentage of patients with an increase in serum prolactin
level above the upper limit of the reference range of 23 ng/
mL was 10.3% for placebo, 4.1% for aripiprazole 20 mg/
day, 3.3% for aripiprazole 30 mg/day, and 90.5% for
risperidone. Mean changes in QTc interval were –2.18
milliseconds for placebo, 0.97 milliseconds for aripiprazole
20 mg/day, –2.35 milliseconds for aripiprazole 30 mg/day,
and 6.31 milliseconds for risperidone. Although no patients
receiving aripiprazole or placebo had a QTc of 450
milliseconds or more and a 10% or greater increase from
baseline, this occurred in 3% of those receiving risperidone.
There were no clinical differences in vital signs or laboratory
abnormalities (except for prolactin) among the four groups.
Because clinical trials include a relatively small number
of patients, and furthermore have stringent inclusion and
exclusion criteria that usually exclude patients with
comorbid conditions, information on some of the more
uncommon adverse events come from isolated case reports.
For example, neuroleptic malignant syndrome in association
with aripiprazole was reported in a case report of an
antipsychotic-naïve person with a history of
methamphetamine and cannabis abuse (Srephichit et al
2006), in a case of a person with depression also treated
with fluoxetine (Duggal and Kithas 2005), in a 17-year-old
adolescent with schizophrenia who had already been
exposed to other second-generation antipsychotics (Spalding
et al 2004), and in a 42-year-old male with a 28-year history
of schizophrenia (Chakraborty and Johnston 2004). Dew et
al (2005) report on a 13-year-old girl with established
neuroleptic malignant syndrome after receiving olanzapine
and haloperidol. After a protracted course where she
received treatment with dantrolene, bromocriptine, and
electroconvulsive therapy, she was given aripiprazole to
alleviate her symptoms of agitation and potential psychosis,
with resultant worsening of tachycardia and rise in serum
creatinine kinase level.
Galactorrhea has been reported in a 29-year-old woman
with schizoaffective disorder when aripiprazole was started
and haloperidol dose was decreased (Ruffatti et al 2005),
and in a 36-year-old woman with schizophreniform disorder
who had received trifluoperazine 3 years previously without
incident (Mendhekar and Andrade 2005). On the other hand,
aripiprazole was successfully used to resolve antipsychotic
induced symptomatic hyperprolactinemia, including
galactorrhea, in female patients with schizophrenia age 19–
40 years (Lee et al 2006).
In summary, aripiprazole was well tolerated among the
patients with schizophrenia who participated in the acute
and long-term studies. Aripiprazole was associated with
lower rates of elevated prolactin than risperidone,
haloperidol, perphenazine, and olanzapine, and consistently
lower rates of extrapyramidal effects than haloperidol or
perphenazine. Weight and metabolic adverse effects were
observed more often with olanzapine than with aripiprazole.
Aripiprazole had a more favorable profile than risperidone
for QTc prolongation. Rare occurrences of neuroleptic
malignant syndrome have been reported, as well as case
reports of galactorrhea, although the latter has also been
reported to resolve with the use of aripiprazole.
Bipolar disorder
In the clinical trials comparing aripiprazole with placebo
among patients with bipolar disorder, aripiprazole appeared
to be well tolerated. In the study reported by Keck et al
(2003), there were no differences in discontinuation rates
between aripiprazole and placebo attributable to adverse
events. However, gastrointestinal (GI) adverse events
including nausea, dyspepsia, vomiting, and constipation,
were more common with aripiprazole than with placebo
(23%, 22%, 16%, and 13% vs 10%, 10%, 5%, and 6%,
respectively). Somnolence was reported in 20% of patients
receiving aripiprazole and in 5% of patients on placebo.
Anxiety was reported in 18% of aripiprazole patients and
in 10% of patients randomized to placebo. Akathisia was
reported in 11% of the patients receiving aripiprazole, and
in 3% of patients assigned to placebo. Changes from baseline
on the scales measuring extrapyramidal effects, including
akathisia, were small, but statistically greater among those
receiving aripiprazole than placebo. No problems were
identified for bodyweight, prolactin elevation, QTcNeuropsychiatric Disease and Treatment 2006:2(4) 438
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prolongation, vital signs, or laboratory analyses. Similar
tolerability outcomes were seen in the study report from
Sachs et al (2006); however, the incidence of treatment-
emergent akathisia was higher at 17.6% for aripiprazole and
4.5% for placebo. A significant difference was observed
between the two groups at endpoint in mean change from
baseline in akathisia rating scores, but this was small in
magnitude. At endpoint, there was no significant difference
between aripiprazole and placebo in the number of patients
with clinically significant akathisia rating scale scores. The
spontaneous reports of akathisia among the patients
receiving aripiprazole were generally mild to moderate in
severity and primarily occurred early in treatment, and rarely
led to discontinuations or reduction in dose. The report by
Sachs et al (2006) also described the time course of
somnolence, nausea, dyspepsia, and constipation as being
limited mainly to the first week of treatment.
In the 26-week maintenance phase of the double-blind
study comparing aripiprazole with placebo (Bristol-Myers
Squibb 2003a; Keck et al 2006), there were no adverse
events in the aripiprazole group with at least a 10% incidence
and twice the incidence of the placebo group. Treatment-
emergent adverse events reported by patients receiving
aripiprazole at an incidence of at least 5% and twice the
incidence of placebo were tremor, akathisia, vaginitis, and
pain in the extremities. The analysis of movement disorder
scales demonstrated no significant differences between
aripiprazole and placebo. There was a statistically significant
difference in favor of aripiprazole in mean change from
randomization to endpoint in prolactin level. Although the
incidence of elevated creatine phosphokinase (CPK) was
slightly higher in patients receiving aripiprazole (6.76% vs
4.11%) and there were 5 patients receiving aripiprazole with
potentially clinically significant elevated CPK levels, none
of these patients had associated symptoms consistent with
neuroleptic malignant syndrome. There were no problems
identified regarding QTc, vital signs, weight, or physical
examinations.
 In the comparison of aripiprazole and haloperidol (Vieta
et al 2005), the most frequent treatment-emergent adverse
events were extrapyramidal syndrome, akathisia, and
depression for haloperidol (35.5%, 23.1%, and 14.2%
respectively), and insomnia, akathisia, and depression for
aripiprazole (13.7%, 11.4%, and 11.4% respectively). It
should be emphasized that anticholinergic agents were
 not
permitted for symptomatic or prophylactic treatment of
extrapyramidal symptoms during the study, contributing to
the rates of extrapyramidal syndrome reported in the study,
and contributing to the high discontinuation rate for patients
receiving haloperidol.
  Other differences between
aripiprazole and haloperidol include serum prolactin
elevations (mean decrease for aripiprazole but a mean
increase for haloperidol). No differences were seen for mean
change in bodyweight, except when the data were stratified
by initial BMI, resulting in the observation that patients in
the high baseline BMI category lost an average of 0.86 kg
on aripiprazole, but gained an average of 0.41 kg on
haloperidol. There were no differences observed in QTc,
vital signs, or laboratory measures.
In summary, aripiprazole appears to be well tolerated in
patients with bipolar disorder. Although akathisia and GI
complaints emerged at the start of treatment in some patients,
GI symptoms in particular may be time-limited in many
instances. Haloperidol was associated with greater rates of
extrapyramidal symptoms than aripiprazole. There is a lack
of comparative safety data with other second-generation
antipsychotics among patients with bipolar disorder.
Optimal dose
Dosing in schizophrenia
The recommended starting and target dose of aripiprazole
for patients with schizophrenia, as approved by regulatory
agencies, is 10 or 15 mg/day, taken once a day without regard
to meals (Bristol-Myers Squibb 2006). The product labeling
provides the following additional information: “…doses
higher than 10 or 15 mg/day, the lowest doses in these trials,
were not more effective than 10 or 15 mg/day. Dosage
increases should not be made before 2 weeks, the time
needed to achieve steady state”. Because these
recommendations are the result of registration studies that
were used in evaluating aripiprazole for commercialization,
these recommendations may not always apply in actual
clinical practice. The patients enrolled in such trials may
not be representative of the general clinical population in
need of treatment – patients in registration trials need to
provide informed consent, be free of alcohol or substance
abuse, be in good physical health, be able to tolerate a
washout off medication, be able to be treated with a
monotherapy, and not be treatment resistant (Citrome and
Volavka 2002; Citrome et al 2005b, 2005c). Dosing of
antipsychotics in more challenging clinical populations may
be quite different than the dosing used in registration trials.
For example, among patients (80% diagnosed with
schizophrenia or schizoaffective disorder) hospitalized
within facilities operated by the New York State Office ofNeuropsychiatric Disease and Treatment 2006:2(4) 439
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Mental Health in the second quarter of 2003, the average
dose of aripiprazole was 22.4 mg/day (standard deviation
11.0). Over half of the patients receiving aripiprazole were
receiving doses in excess of 15 mg/day (Citrome et al 2005c),
and 11.4% were receiving doses in excess of the product
label maximum of 30 mg/day (unpublished).
Although the registration studies of aripiprazole have
failed to demonstrate a dose-response relationship for
efficacy, and there are no fixed-dose studies of aripiprazole
examining efficacy of doses in excess of 30 mg/day, there
have been other studies that may help in evaluating dose.
The Bristol-Myers Squibb Clinical Trials Disclosure
Database and a report in press (Tandon et al 2006) describe
a study (CN138-087) that randomized (in a 4:1 ratio) 1599
patients with schizophrenia to receive either aripiprazole
open label within the range of 10–30 mg/day or “standard
of care” treatment consisting of a single new antipsychotic
medication based on the investigator’s judgment and dosed
according to the package insert (Bristol-Myers Squibb
2004d). The study was conducted in a general psychiatric
practice environment at 292 different sites and each patient
could participate up to 24 weeks or until aripiprazole became
commercially available (whichever was sooner). The study
had very broad inclusion criteria: diagnosis of schizophrenia
or schizoaffective disorder for whom an alteration in
medication was clinically reasonable or initiation of
antipsychotic treatment was required. A total of 1295 patients
were randomized to aripiprazole, and 65% completed 8
weeks of treatment. The mean dose of aripiprazole at
endpoint was 20 mg/day; at Week 8, 47% who completed
the study were receiving 15 mg/day and 29% were receiving
30 mg/day. Thus, results from a broad effectiveness trial
indicate that many completers required dosing of
aripiprazole that was higher than what was recommended
in the product label, and in line with data from an in-patient
public psychiatric hospital setting. Systematic studies on
dose of aripiprazole greater than 30 mg/day are not available
with the exception of one report presented as a poster (Saha
et al 2002). The safety, tolerability, and pharmacokinetics
of escalating doses of aripiprazole from 30 to 90 mg/day
were evaluated among 40 patients with stable schizophrenia
or schizoaffective disorder. Patients were randomized to
30 mg/day (N=12), 45 mg/day (N=7), 60 mg/day (N=7),
75 mg/day (N=7), and 90 mg/day (N=7) for 15 days of
treatment at that dose. Linear pharmacokinetics was
observed. Incidence of adverse events was similar across
dose groups, with the exception of akathisia and tachycardia
which appeared higher at 90 mg/day (frequency of 57% and
71% respectively). Patients in all dose groups maintained a
stable symptom profile. Thus, dosing above 30 mg/day
appears generally tolerable. More information is required
regarding efficacy, but higher doses may be helpful for some
patients. A recent case report describes the use of
aripiprazole 75 mg/day in a 21-year-old woman with
paranoid schizophrenia (Duggal and Mendhekar 2006)
where symptomatic improvement occurred when the dose
was gradually increased in several steps. On the other hand,
reports of worsening psychosis when aripiprazole is added
to the antipsychotic regimen for some patients is of concern
(DeQuardo 2004; Ramaswamy et al 2004; Reeves and Mack
2004), and careful titration upwards may be the best course
of action to minimize this risk. When aripiprazole was first
introduced in 2002, the smallest dosage strength available
was 10 mg. Since then, a 5-mg tablet and an oral solution
(1 mg/mL) have become available (Bristol-Myers Squibb
2006), allowing for a smaller starting dose when tolerability
is a concern. Double-blind, randomized, fixed-dosed studies
of adequate length are desirable to address the utility of
higher dosing for patients with schizophrenia.
Dosing in bipolar disorder
The recommended dose of aripiprazole for patients with
bipolar disorder, as approved by regulatory agencies, is
30 mg/day (Bristol-Myers Squibb, 2006). The product
labeling further adds: “approximately 15% of patients had
their dose decreased to 15  mg based on assessment of
tolerability”. The recommended starting dose of 30 mg/day
stems directly from the registration trials where this strategy
was employed. Little information is known about the relative
merits of higher or lower dosing in terms of efficacy in
controlling manic symptoms. Complicating dose selection
for aripiprazole is the observation that for many patients
with bipolar disorder, combination treatment with lithium
or an anticonvulsant is commonly prescribed. Although not
approved by regulatory agencies for combination with
lithium or valproate, pharmacokinetic studies of aripiprazole
in combination with lithium or valproate do not indicate
any need for dose adjustment based on concerns about
alterations in plasma levels of aripiprazole or its main active
metabolite (Citrome et al 2005d).
Is aripiprazole worth using?
Schizophrenia
Efficacy needs drive antipsychotic selection, tempered by
safety and tolerability issues. Attempts to place aripiprazoleNeuropsychiatric Disease and Treatment 2006:2(4) 440
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into clinical perspective have included a Cochrane
Collaboration review (El-Sayeh and Morganti 2004). All
randomized clinical trials available at the time comparing
aripiprazole with placebo and/or first- or second-generation
antipsychotics for schizophrenia were analyzed. Absent
from the analyses were some data that have only recently
become available, such as what has been posted on the
Bristol-Myers Squibb Clinical Trials Disclosure Database
(for example, study CN138-003). Thus the Cochrane meta-
analysis did not include all information now available on
comparisons of olanzapine and aripiprazole. Nevertheless,
the meta-analysis did calculate clinically relevant measures
such as relative risk (RR), 95% confidence intervals (CI),
and numbers needed to treat (NNT) (Kraemer and Kupfer
2006). Data were presented for 4125 people in 10
randomized studies. Compared with placebo, aripiprazole
significantly decreased relapse in both the short and medium
term (n=300, 1 study, RR 0.66 CI 0.53– 0.81, NNT 5 CI 4–
8). Compared with first-generation antipsychotics, there
were no significant benefits for aripiprazole for global state,
mental state, quality of life, or leaving the study early. When
compared with olanzapine and risperidone, aripiprazole was
no better or worse on outcomes of global state and leaving
the study early. On safety and tolerability, the authors
reported that aripiprazole might decrease prolactin levels
below that expected from placebo (n=305, 1 RCT, RR 0.32
CI 0.13–0.81, NNT 14 CI 11–50). Both aripiprazole and
first-generation antipsychotics demonstrated similar rates
of adverse effects, including akathisia (RR 0.44 CI 0.17–
1.12) and general extrapyramidal effects (RR 0.53 CI 0.18–
1.53). Aripiprazole did, however, cause more insomnia than
perphenazine (n=300, 1 study, RR 2.23 CI 1.57–3.18,
NNH 4 CI 3–9) and less need for antiparkinson drugs
than 10–20 mg/day of haloperidol (n=1854, 4 studies, RR
0.45 CI 0.33–0.60, NNT 4 CI 3–5). The rates of adverse
effects were also similar between aripiprazole and
second-generation antipsychotics (olanzapine and
risperidone), with the exception of less elevation of
prolactin (n=301, 1 study, RR 0.04 CI 0.02–0.08, NNT
2) and less prolongation of the mean QTc (30 mg/day)
(n=200, 1 study, weighted mean difference –10.0, CI
–16.99 to –3.01) compared with risperidone. The
reviewers concluded that aripiprazole may be effective
for the treatment of schizophrenia, but it is not much
different from first-generation antipsychotics and second-
generation antipsychotics in treatment response, efficacy,
or tolerability, and the authors recommended additional
pragmatic short-, medium-, and long-term randomized,
controlled trials to determine its position in everyday
clinical practice. Another critical review was not so
charitable (Prescrire 2005), stating that “in practice, there
is no sound reason to prescribe aripiprazole: its
advantages and disadvantages are not clearly established,
and we already have several treatment alternatives”.
The above reviews, which were clearly independent of
influence by the manufacturer of aripiprazole, address the
difficulty in seeing advantages for new antipsychotics that,
on the whole, are not so different from their predecessors
when compared among groups of patients. What is missing
is consideration of the common clinical observation that
response, both in terms of efficacy and tolerability, to a
specific antipsychotic, varies greatly from individual to
individual and that practitioners need to be able to craft
individually tailored medication regimens. New information
about aripiprazole, not included in the Cochrane meta-
analysis, accentuates this issue. Namely, a large study
(CN138-003) demonstrated overall differences between
olanzapine and aripiprazole (Bristol-Myers Squibb 2005) –
olanzapine was superior to aripiprazole in efficacy but not
as well tolerated in terms of metabolic issues. In most cases,
this is not a therapeutic dilemma per se – not all patients
receiving olanzapine develop significant metabolic
problems, and many patients respond quite well to
aripiprazole. In a consensus panel report supported by the
manufacturer of aripiprazole (Travis et al 2005), aripiprazole
was noted to be at least as effective as other antipsychotics
in the treatment of patients with schizophrenia aged 18–65
years, and that its favorable side-effect profile may make it
an appealing choice for patients with first onset of psychosis
or patients who have experienced problems with side-effects
while receiving other antipsychotic medications. Thus,
aripiprazole can be considered a first-line treatment. It
appears that aripiprazole may be a useful option when
switching patients from a poorly tolerated antipsychotic,
but it is unclear how useful it would be for patients who
require a switch because of poor efficacy with another
antipsychotic. It is anticipated that the Phase 3 results of
the Clinical Antipsychotic Trials of Intervention
Effectiveness (Lieberman et al 2005) will provide additional
information on switching to open-label aripiprazole from a
variety of blinded antipsychotics or from open-label
clozapine. The issue of using aripiprazole as an augmenting
agent to other antipsychotics has not yet been reported in a
randomized, double-blind, clinical trial, although case
reports exist of combinations of olanzapine or clozapine
with aripiprazole resulting in increased efficacy orNeuropsychiatric Disease and Treatment 2006:2(4) 441
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tolerability (Duggal 2004; Lim et al 2004; Ziegenbein et al
2005; Clarke et al 2006; Henderson et al 2006). However,
addition of aripiprazole to first- and second-generation
antipsychotics has also been associated with exacerbation
of symptoms (DeQuardo 2004; Reeves and Mack 2004;
Ramaswamy et al 2004; Barnas et al 2005; Glick et al
2006). Thus, at the present time, caution should be
exercised when using aripiprazole in combination with
other antipsychotics.
Bipolar disorder
Second-generation antipsychotics have emerged as “mood
stabilizers”, rivaling classic agents such as lithium and
certain anticonvulsants such as valproate and carbamazepine
(Citrome et al 2005a). The second-generation
antipsychotics, as monotherapies, can successfully treat
bipolar mania, even in the absence of psychotic symptoms,
as demonstrated by many clinical trials. Safety and
tolerability issues can drive treatment selection, particularly
for the bipolar patient who appears to respond well to a
wide array of agents. For example, because of the potential
teratogenic effects of valproate and lithium, second-
generation antipsychotics are perhaps more desirable
alternatives for female patients who are actively seeking to
bear children. The occurrence of adverse effects on one
agent, for example weight gain with olanzapine, may prompt
a switch to another agent. Aripiprazole appears to have a
low propensity for weight gain, a favorable metabolic
profile, and no association with hyperprolactinemia. Clinical
trials that directly compare aripiprazole with other second-
generation antipsychotics, as well as lithium, valproate, and
carbamazepine, would provide additional perspectives on
the utility of aripiprazole for the treatment of bipolar
disorder, including issues such as suitability as a first-choice
treatment.
Conclusions
Aripiprazole is approved by regulatory agencies for the
treatment of schizophrenia and bipolar disorder. Among the
second-generation antipsychotics it has the unique property
of being a dopamine partial agonist; however, aripiprazole
shares with the rest of this antipsychotic class substantial
antagonist activity at the serotonin 5HT2A receptor. Efficacy
in the short- and long-term treatment of schizophrenia has
been established in placebo-controlled trials, and
aripiprazole appears superior in efficacy to haloperidol (long
term), similar to perphenazine and risperidone, and inferior
to olanzapine. The tolerability profile of aripiprazole among
patients with schizophrenia appears superior to haloperidol,
perphenazine, risperidone, and olanzapine. Aripiprazole has a
low propensity for weight gain, a favorable metabolic profile,
and no association with hyperprolactinemia. Information on
the efficacy of aripiprazole in the treatment of bipolar disorder
is more limited, particularly in terms of comparisons with other
second-generation antipsychotics for which there are no
reported trials. Compared with placebo, aripiprazole is
efficacious in treating acute manic or mixed episodes associated
with bipolar I disorder, is superior to placebo for preventing
relapse to mania (but not depression), and superior to
haloperidol in maintenance of response. Tolerability of
aripiprazole among patients with bipolar disorder is generally
good; however, some patients can develop treatment-emergent
akathisia and GI symptoms, with the latter usually resolving
with time in many instances. Dosing of aripiprazole for
schizophrenia is unclear, with product labeling suggesting a
starting and target dose of 10 or 15 mg/day but broader-based
clinical trials and clinical practice demonstrate general use of
aripiprazole at higher doses. However, lower dosing may be
important in individualizing therapy to improve tolerability,
with lower starting doses becoming more important when
adding to, or switching from, another antipsychotic. Dosing of
aripiprazole for treatment of manic or mixed episodes was set
at 30 mg/day in the registration trials for that indication, and
there are no data currently available for review from studies
that used multiple fixed doses that would address the question
if different dose regimens would be any more or less efficacious
than 30 mg/day. The overall favorable tolerability profile of
aripiprazole makes it an attractive option for the treatment of
both schizophrenia and bipolar disorder.
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